Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Morbidity of Graves' Disease and Recurrence Rate of Hyperthyroidism Due to Epstein-Barr Virus Lytic Reactivation

NCT06426758 is registered in ClinicalTrials.gov with Xiao-Ming Mao as lead sponsor.

NCT NCT06426758
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06426758 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Morbidity of Graves' Disease and Recurrence Rate of Hyperthyroidism Due to Epstein-Barr Virus Lytic Reactivation
Lead sponsor
Xiao-Ming Mao
Phase
Observational
Overall status
Not yet recruiting
Start date
May 30, 2024
Completion date
September 1, 2027
Enrollment
300 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

epstein-barr virus, graves disease, graves' disease in remission